Hematopoietic Stem Cell Transplantation Clinical Trial
Official title:
Fitness in Allogeneic Stem Cell Transplantation
Purpose: The primary hypothesis of this study is that the combination of interval exercise
training (IET) as well as motivational accelerometry (MA) delivered both as a 5-12 week
intervention that will improve cardiorespiratory fitness in patients preparing to undergo
allogeneic hematopoietic cell transplantation (alloHCT). MA is not an established term, but
in respect to this study, MA refers to the use of wearable accelerometry paired with regular
intervals of physical activity coaching from members of the study staff during the IET
training. The study will also look at several secondary endpoints including the association
of the intervention with changes in cyclin-dependent kinase inhibitor 2A, multiple tumor
suppressor 1 (p16INK4a), and the association of the intervention with changes in symptoms and
quality of life before and after transplant.
Participants: 60 patients will be randomized into two groups, 30 in the intervention group
consisting of both IET and MA, and 30 in the control group applying usual care and use of
wearable accelerometry without motivational physical activity coaching.
Procedures (methods): Results of this study will inform a randomized, multi-site study of a
pre-transplant exercise intervention.
The investigator team for the current protocol has recently completed a single-arm pilot
protocol (LCCC 1311) of a 6-week home-based unsupervised IET program (goal of three IET
sessions per week, 65%-95% Max Heart Rate [MHR]) in patients planning to undergo alloHCT. In
our study, participants preparing to undergo alloHCT experienced an average 3.8ml/kg*min
improvement in peak volume of oxygen consumed (VO2peak) from pre to post-intervention.
Patients in LCCC 1311 wore FitBit accelerometers throughout the study period.
The primary purpose of the current randomized controlled trial is to determine, in patients
preparing to undergo alloHCT, whether an intervention comprised of interval exercise training
and motivational accelerometry (IET/MA) will improve cardiorespiratory fitness more than the
control group who receives usual care and an accelerometer without motivational physical
activity coaching. The study will also look at several secondary endpoints including the
association of the intervention with changes in p16INK4a, and the association of the
intervention with changes in symptoms and quality of life before and after transplant.
This randomized controlled trial will include 60 patients preparing to undergo alloHCT (30 in
the intervention group, 30 in the control group). We plan to analyze the effect of IET/MA on
VO2peak. Subjects will be recruited after their transplant teams have determined that they
will undergo alloHCT within the subsequent 5-12 weeks. Following recruitment, patients will
undergo baseline fitness assessments consisting of cardiorespiratory exercise testing using
indirect calorimetry on a cycle ergometry (for the assessment of VO2peak), 6 minute walk
distance testing, and baseline physical activity, symptom and quality of life questionnaires.
Participants randomized to the IET/MA group will then receive an individualized IET/MA
prescription for a duration of at least 5 weeks, up until the time of admission for alloHCT
or 12 weeks from the initiation of IET/MA, whichever occurs first. The mode of exercise can
be walking, jogging, running, cycling, elliptical, stair climbing, or a combination of these,
and will be performed unsupervised at home. For the first week, participants will be asked to
engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and
beyond, participants will undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and
five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of
recovery/light activity in between each interval. Each exercise session is a total of 30
minutes. Fitness assessments will be completed at the end of the intervention period, at the
time of admission for alloHCT. Based on the improvement in VO2peak seen in the pre-alloHCT
patient population in LCCC 1311, the current study is powered to detect a 3.8ml/kg*min
VO2peak improvement in the intervention group relative to the control group.
All participants in both groups will be provided with a FitBit Surge accelerometer.
Participants in the intervention group will also receive weekly motivation from a study team
member to achieve a 10% week over week improvement in average steps/day. Participants in the
control group will not receive this physical activity coaching. Participants will continue to
wear the accelerometers after the intervention and until 1 year following alloHCT.
Participants in both groups will have blood drawn for p16INK4a levels before and after the
IET intervention. Participants in both groups will also complete symptom and quality of life
questionnaires before the intervention and periodically throughout the year following alloHCT
(please see study plan and time and events tables).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00766883 -
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT06148610 -
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
|
||
Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01714557 -
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00701688 -
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Completed |
NCT00023530 -
Blood and Marrow Transplant Clinical Research Network
|
N/A | |
Recruiting |
NCT04092309 -
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
|
N/A | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT02663622 -
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
|
Phase 2 | |
Recruiting |
NCT04937634 -
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT04203108 -
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
|
Phase 4 | |
Withdrawn |
NCT03279133 -
Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.
|
Phase 4 | |
Completed |
NCT03654599 -
Effects of Digital Stories Intervention on Psychosocial Well-being
|
N/A | |
Completed |
NCT05151406 -
Myths and Misconceptions About HSCT in a Limited Resource Region
|
N/A | |
Completed |
NCT02241005 -
Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci
|
N/A | |
Recruiting |
NCT03689465 -
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
|
Phase 4 | |
Recruiting |
NCT04868786 -
Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT03010579 -
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation
|
Phase 4 | |
Active, not recruiting |
NCT00959140 -
Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors
|
N/A |